Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences, Inc. reported the results of its Annual Meeting of Stockholders. A total of 41,728,676 shares of common stock, representing 67.9% of outstanding shares, were present or represented, providing a solid quorum for the meeting’s business.
Stockholders elected Mary Szela and Gary Gordon as directors to serve three-year terms expiring at the 2029 annual meeting. The appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026 was also ratified by a wide margin.
On executive compensation matters, stockholders approved a three-year frequency for future advisory votes on named executive officer pay, and approved the current compensation of named executive officers on an advisory basis. Following the vote, the Board decided the company will hold say-on-pay votes every three years.
TriSalus Life Sciences, Inc. reported first‑quarter 2026 revenue of $8.9 million, slightly below the prior year’s $9.2 million, but generated net income of $1.5 million versus a $10.4 million loss a year earlier. The swing to profit was driven mainly by non‑cash gains from remeasuring warrant, earnout and revenue‑based redemption liabilities.
Gross profit held essentially flat at $7.7 million, while operating expenses rose modestly as the company continued investing in R&D and commercial growth for its PEDD delivery systems and nelitolimod. Cash and cash equivalents increased sharply to $56.6 million, primarily from a February equity offering that raised about $42.6 million net.
Total assets doubled to $71.0 million, and stockholders’ equity improved from a deficit of $33.9 million at year‑end 2025 to positive equity of $12.8 million at March 31, 2026. Long‑term debt under the OrbiMed credit facility remained around $33.1 million, with associated warrants and revenue‑based redemption obligations continuing to be marked to fair value each quarter.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million from its TriNav system, a 2.9% decrease from the same period in 2025, while gross margin improved to 86.2% from 83.7% as unit costs fell.
Operating loss widened slightly to $8.4 million, driven mainly by higher sales and marketing and stock-based compensation tied to commercial expansion. However, changes in the fair value of derivatives and earnout liabilities produced non-cash gains of $11.3 million, turning results into net income of $1.5 million, or $0.03 per share, versus a prior-year loss.
On a non-GAAP basis, adjusted EBITDA loss was $5.8 million, modestly higher than a year ago. The company raised $46.0 million in gross proceeds from an equity offering, ending March 31, 2026 with $56.6 million in cash and cash equivalents. Management revised 2026 revenue guidance to a range of $54 million to $57 million and highlighted ongoing clinical and commercial progress for its PEDD platform and nelitolimod program.
TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026. The filing notes ownership declined by more than 1% versus 09/30/2025 due to an increase in outstanding shares. The report is signed by Ian Maidens, Group CFO, on 05/05/2026.
TriSalus Life Sciences, Inc. announced that Jodi Devlin has notified the company of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The company previously appointed Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, helping support continuity in its clinical and medical leadership.
Frankenius Equity AB, a more than 10% holder of TriSalus Life Sciences, Inc., converted its entire Series A Convertible Preferred Stock into common shares. On July 31, 2025, it exchanged 230,000 preferred shares for 759,000 shares of common stock under a company exchange offer.
The offer calculates common shares using the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Frankenius Equity directly holds 6,989,748 TriSalus common shares, replacing its prior preferred position with ordinary equity.
TriSalus Life Sciences, Inc. appointed Richard Marshall, M.D. as Chief Medical Officer, effective June 29, 2026. He will move into this full-time role from his current position as Medical Director and will lead medical strategy, clinical development and evidence generation across the company’s oncology programs.
Under his offer letter, Dr. Marshall will receive an annual base salary of $525,000, a $250,000 sign-on bonus, and will be eligible for an annual bonus of up to 50% of base salary based on Board-determined goals. Following his start date, the Board will be asked to grant him 120,000 stock options and 60,000 restricted stock units, with further annual equity grants possible under the Equity Incentive Plan.
The accompanying press release highlights Dr. Marshall’s background in interventional oncology and his role in supporting TriSalus’ Pressure-Enabled Drug Delivery platform, TriNav devices and investigational immunotherapy nelitolimod as the company advances treatments for solid tumors.
TriSalus Life Sciences director David J. Matlin converted preferred stock into common shares under a company offer. On July 31, 2025, all 100,000 shares of Series A Preferred Stock held by Matlin were converted into 330,000 shares of common stock.
The conversion followed an exchange offer allowing all preferred holders to receive common shares equal to the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Matlin directly owned 1,271,944 common shares and no remaining preferred shares.
TriSalus Life Sciences, Inc. will hold its 2026 virtual annual stockholder meeting on May 14, 2026 at 10:00 a.m. Eastern Time via live audio webcast at https://www.virtualshareholdermeeting.com/TLSI2026 for holders of record as of March 20, 2026.
Stockholders will vote on four items: electing two Class III directors (Mary Szela and Gary Gordon) to serve until the 2029 meeting, ratifying Grant Thornton LLP as independent auditor for 2026, an advisory “say-on-frequency” vote where the Board recommends a three-year cycle, and an advisory “say-on-pay” vote on 2025 executive compensation.
The proxy explains virtual participation and voting mechanics for registered and beneficial owners, outlines board and committee structure, and details 2025 pay for named executive officers, including total compensation of $4,823,349 for CEO Mary Szela.